1. Home
  2. SWKH vs TLSA Comparison

SWKH vs TLSA Comparison

Compare SWKH & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SWKH
  • TLSA
  • Stock Information
  • Founded
  • SWKH 1996
  • TLSA 2013
  • Country
  • SWKH United States
  • TLSA United Kingdom
  • Employees
  • SWKH N/A
  • TLSA N/A
  • Industry
  • SWKH Diversified Financial Services
  • TLSA Biotechnology: Pharmaceutical Preparations
  • Sector
  • SWKH Finance
  • TLSA Health Care
  • Exchange
  • SWKH Nasdaq
  • TLSA Nasdaq
  • Market Cap
  • SWKH 179.1M
  • TLSA 187.0M
  • IPO Year
  • SWKH 1999
  • TLSA 2000
  • Fundamental
  • Price
  • SWKH $14.62
  • TLSA $1.66
  • Analyst Decision
  • SWKH Strong Buy
  • TLSA
  • Analyst Count
  • SWKH 1
  • TLSA 0
  • Target Price
  • SWKH $18.00
  • TLSA N/A
  • AVG Volume (30 Days)
  • SWKH 12.9K
  • TLSA 369.4K
  • Earning Date
  • SWKH 08-14-2025
  • TLSA 05-06-2025
  • Dividend Yield
  • SWKH N/A
  • TLSA N/A
  • EPS Growth
  • SWKH 55.18
  • TLSA N/A
  • EPS
  • SWKH 1.41
  • TLSA N/A
  • Revenue
  • SWKH $37,409,000.00
  • TLSA N/A
  • Revenue This Year
  • SWKH $52.93
  • TLSA N/A
  • Revenue Next Year
  • SWKH N/A
  • TLSA N/A
  • P/E Ratio
  • SWKH $10.36
  • TLSA N/A
  • Revenue Growth
  • SWKH 47.31
  • TLSA N/A
  • 52 Week Low
  • SWKH $12.00
  • TLSA $0.63
  • 52 Week High
  • SWKH $16.24
  • TLSA $2.60
  • Technical
  • Relative Strength Index (RSI)
  • SWKH 47.97
  • TLSA 40.76
  • Support Level
  • SWKH $14.38
  • TLSA $1.73
  • Resistance Level
  • SWKH $15.20
  • TLSA $1.90
  • Average True Range (ATR)
  • SWKH 0.29
  • TLSA 0.15
  • MACD
  • SWKH 0.06
  • TLSA -0.05
  • Stochastic Oscillator
  • SWKH 55.04
  • TLSA 24.19

About SWKH SWK Holdings Corporation

SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.

Share on Social Networks: